SEC Filing Summary: BioSig Technologies, Inc. (Form 8-K)
Business Context and Reporting Period
This Current Report on Form 8-K was filed by BioSig Technologies, Inc. (not Streamex Corp.) on November 9, 2017, reporting events occurring on November 3, 2017. The filing details a material definitive agreement involving a private placement of equity securities and amendments to the company's Articles of Incorporation.
Key Financial Metrics and Transaction Details
The filing does not provide standard financial statements (revenue, profit, cash flow, or margins) as it is a current report on a specific transaction. Key transaction metrics include:
- Total Capital Raised: $2,000,000 in aggregate consideration.
- Securities Issued: 1,334 shares of Series D Preferred Stock and Class A Warrants to purchase 667,000 shares of Common Stock.
- Preferred Stock Terms: Stated value of $1,500 per share; 9% cumulative annual dividend; liquidation preference of stated value plus accrued dividends.
- Warrant Terms:
- Class A Warrants: Exercise price of $1.75 per share; expire May 3, 2021.
- Class B Warrants (exchange of existing warrants): Exercise price of $1.50 per share; expire November 3, 2020.
- Anti-Dilution: Both Preferred Stock and Warrants include "full ratchet" anti-dilution protection.
Material Changes and Agreements
The primary material change is the entry into a Securities Purchase Agreement with institutional accredited investors. Concurrently, the company exchanged 780,506 outstanding warrants for new Class B Warrants with identical terms. The company also filed a Certificate of Designations for the Series D Preferred Stock, establishing conversion rights at $1.50 per share and a potential early conversion premium of $270 per $1,000 of stated value if converted prior to November 3, 2020.
Guidance, Risks, and Contingencies
Registration Rights and Penalties: The company agreed to file a registration statement within 45 days of closing to cover the resale of the new securities. Failure to file or obtain effectiveness within specified timelines triggers liquidated damages of 1% of the aggregate purchase price per day of delinquency, capped at 10% of the total purchase price.
Covenants: The Purchase Agreement prohibits the company from entering into equity line financings or other variable rate transactions.
Dividend Payment Risk: While dividends are cumulative at 9% per annum, payment in Common Stock is subject to specific equity conditions. The company has the option to pay dividends in cash, stock, or a combination.
Investor Verification Checklist
- Verify the company's current cash position to assess its ability to pay the 9% cumulative dividends on the Series D Preferred Stock.
- Confirm the status of the registration statement filing required within 45 days of November 3, 2017, to avoid liquidated damages.
- Review the "full ratchet" anti-dilution provisions to understand potential dilution impacts on existing common shareholders if future equity is issued below $1.50 or $1.75.
- Check for any subsequent equity issuances that may have triggered the early conversion premium or anti-dilution adjustments.
- Confirm the company's compliance with the covenant prohibiting equity line financings.